Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tb-161-DOTAGA-Glu-(FAPI)2
- Development stage
- Unknown
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tb-161-DOTAGA-Glu-(FAPI)2 is an investigational, next-generation dimeric radioligand therapy designed to target fibroblast activation protein (FAP). The drug consists of a dimeric FAP inhibitor (DOTAGA-Glu-(FAPI)2) labeled with the therapeutic radionuclide terbium-161 (Tb-161). The dimeric structure of the targeting ligand provides enhanced tumor uptake and prolonged tumor retention compared to monomeric FAP inhibitors. Terbium-161 is an emerging radionuclide that offers a therapeutic advantage over lutetium-177 by emitting both low-energy beta particles and short-range Auger electrons, delivering a highly localized radiation dose to micro-metastases while sparing surrounding healthy tissue. The agent is being developed by Telix Pharmaceuticals (as part of its TLX400 program) in collaboration with the Thera4Care consortium for the treatment of FAP-expressing advanced solid tumors, including sarcomas, ovarian cancer, and pancreatic cancer.
- Other names
- 161Tb-DOTAGA-Glu-(FAPI)2161Tb-DOTAGA.Glu.(FAPi)2161Tb-TLX400Tb-161-DOTAGA.Glu.(FAPi)2Tb-161-TLX400Tb161-TLX400Tb 161-TLX400terbium-161-DOTAGA-Glu-(FAPI)2
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on Tb-161-DOTAGA-Glu-(FAPI)2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tb-161-DOTAGA-Glu-(FAPI)2.